Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

The primary rhegmatogenous detachment cohort will have the following selection criteria: Inclusion criteria: * Patients \> 18 years old * Patients presenting for primary rhegmatogenous retinal detachment repair within 28 days of symptom onset * Patients undergoing vitrectomy or vitrectomy with scleral buckle Exclusion criteria: * Patient unable to give consent * Patient unable to follow-up * Prior history of retinal detachment incisional surgery in presenting eye * Prior history of open globe injury to presenting eye * Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery, actively on glaucoma medication * Prior history of corneal disease, or history of corneal edema * Patient already on topical netarsudil in presenting eye * Patient without natural lens or intraocular lens implant (I.e., aphakic patients) * Patients with intraocular pressure \<8mm Hg in operative eye * Active or chronic or recurrent uncontrolled ocular or systemic disease * Active or history of chronic or recurrent inflammatory eye disease * Diagnosis of proliferative diabetic retinopathy * Signs of ocular infection at presentation in either eye * Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively * Inability to use/ apply topical eye drops The proliferative vitreoretinopathy cohort will have the following selection criteria: Inclusion criteria: * Patients \> 18 years old * Patient presenting with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma * Patients undergoing vitrectomy or vitrectomy with scleral buckle Exclusion criteria: * Patient unable to give consent * Patient unable to follow-up * Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery * Patient already on topical netarsudil in presenting eye * Patients with intraocular pressure \<8mm Hg in operative eye * Active or chronic or recurrent uncontrolled ocular or systemic disease * Active or history of chronic or recurrent inflammatory eye disease * Diagnosis of severe nonproliferative or proliferative diabetic retinopathy or vasoproliferative disease in operative eye * Signs of ocular infection at presentation in either eye * Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively * Inability to use/ apply topical eye drops * No Light Perception vision in operative eye * Failure to achieve intraoperative reattachment